Cargando…
Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care
BACKGROUND: Antiretroviral therapy (ART) has significantly decreased HIV/AIDS-related morbidity and mortality. However, globally, many people living with HIV die from non-AIDS related illnesses including liver diseases which occur partly due to co-infection with HBV and or HCV. The aim of this study...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499983/ https://www.ncbi.nlm.nih.gov/pubmed/31053100 http://dx.doi.org/10.1186/s12879-019-4027-y |
_version_ | 1783415864486264832 |
---|---|
author | Pappoe, Faustina Hagan, Charles Kofi Oheneba Obiri-Yeboah, Dorcas Nsiah, Paul |
author_facet | Pappoe, Faustina Hagan, Charles Kofi Oheneba Obiri-Yeboah, Dorcas Nsiah, Paul |
author_sort | Pappoe, Faustina |
collection | PubMed |
description | BACKGROUND: Antiretroviral therapy (ART) has significantly decreased HIV/AIDS-related morbidity and mortality. However, globally, many people living with HIV die from non-AIDS related illnesses including liver diseases which occur partly due to co-infection with HBV and or HCV. The aim of this study was to determine the seroprevalence of HBV and HCV among HIV infected individuals receiving care from three different hospitals in the Central Region of Ghana. METHODS: This research was a case-case study. The population consisted of ART naive persons (newly confirmed HIV cases) and those who had been on ART for more than 3 months (old cases). Each individual’s sociodemographic characteristics and clinical data including their HBV and HCV status were collected. Those who knew their HBV and HCV status and those who did not know their status were tested for circulating HBsAg and anti-HCV using rapid diagnostic test cassettes. Descriptive analysis was done, and the data presented as median with interquartile range, frequency and percentage. Fisher’s exact test and Pearson Chi-square (χ(2)) test were used to determine associations between categorical variables. RESULTS: Overall, 394 HIV individuals aged, 3 to 76 years old with a median age of 41 (IQR:34–49) participated in this study. Circulating HBsAg and anti-HCV were detected in 6.1% (24/394) and 0.5% (2/393) participants respectively with an overall seroprevalence of 6.6% (26/394). None of the participants was positive for both HBV and HCV infections. 92.1% (363/394) had no information on their HBV status while all the 394 participants did not know their HCV status during data collection. No significant association of HBV infection rate was found in all the socio-demographic data of the participants. But HBV infection rates were significantly higher in those at WHO clinical stages 2 and 3 (P = 0.004). CONCLUSION: HBV and HCV were detected among the HIV-infected participants. Majority of the participants had no information on their HBV status and none of the participants had information on his or her HCV status. This study recommends the need for policy makers to provide free HBV and HCV screening for all HIV infected individuals for their effective management. |
format | Online Article Text |
id | pubmed-6499983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64999832019-05-09 Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care Pappoe, Faustina Hagan, Charles Kofi Oheneba Obiri-Yeboah, Dorcas Nsiah, Paul BMC Infect Dis Research Article BACKGROUND: Antiretroviral therapy (ART) has significantly decreased HIV/AIDS-related morbidity and mortality. However, globally, many people living with HIV die from non-AIDS related illnesses including liver diseases which occur partly due to co-infection with HBV and or HCV. The aim of this study was to determine the seroprevalence of HBV and HCV among HIV infected individuals receiving care from three different hospitals in the Central Region of Ghana. METHODS: This research was a case-case study. The population consisted of ART naive persons (newly confirmed HIV cases) and those who had been on ART for more than 3 months (old cases). Each individual’s sociodemographic characteristics and clinical data including their HBV and HCV status were collected. Those who knew their HBV and HCV status and those who did not know their status were tested for circulating HBsAg and anti-HCV using rapid diagnostic test cassettes. Descriptive analysis was done, and the data presented as median with interquartile range, frequency and percentage. Fisher’s exact test and Pearson Chi-square (χ(2)) test were used to determine associations between categorical variables. RESULTS: Overall, 394 HIV individuals aged, 3 to 76 years old with a median age of 41 (IQR:34–49) participated in this study. Circulating HBsAg and anti-HCV were detected in 6.1% (24/394) and 0.5% (2/393) participants respectively with an overall seroprevalence of 6.6% (26/394). None of the participants was positive for both HBV and HCV infections. 92.1% (363/394) had no information on their HBV status while all the 394 participants did not know their HCV status during data collection. No significant association of HBV infection rate was found in all the socio-demographic data of the participants. But HBV infection rates were significantly higher in those at WHO clinical stages 2 and 3 (P = 0.004). CONCLUSION: HBV and HCV were detected among the HIV-infected participants. Majority of the participants had no information on their HBV status and none of the participants had information on his or her HCV status. This study recommends the need for policy makers to provide free HBV and HCV screening for all HIV infected individuals for their effective management. BioMed Central 2019-05-03 /pmc/articles/PMC6499983/ /pubmed/31053100 http://dx.doi.org/10.1186/s12879-019-4027-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Pappoe, Faustina Hagan, Charles Kofi Oheneba Obiri-Yeboah, Dorcas Nsiah, Paul Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care |
title | Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care |
title_full | Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care |
title_fullStr | Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care |
title_full_unstemmed | Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care |
title_short | Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care |
title_sort | sero-prevalence of hepatitis b and c viral infections in ghanaian hiv positive cohort: a consideration for their health care |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499983/ https://www.ncbi.nlm.nih.gov/pubmed/31053100 http://dx.doi.org/10.1186/s12879-019-4027-y |
work_keys_str_mv | AT pappoefaustina seroprevalenceofhepatitisbandcviralinfectionsinghanaianhivpositivecohortaconsiderationfortheirhealthcare AT hagancharleskofioheneba seroprevalenceofhepatitisbandcviralinfectionsinghanaianhivpositivecohortaconsiderationfortheirhealthcare AT obiriyeboahdorcas seroprevalenceofhepatitisbandcviralinfectionsinghanaianhivpositivecohortaconsiderationfortheirhealthcare AT nsiahpaul seroprevalenceofhepatitisbandcviralinfectionsinghanaianhivpositivecohortaconsiderationfortheirhealthcare |